1
|
Stino AM, Reynolds EL, Watanabe M, Callaghan BC. Intravenous immunoglobulin and plasma exchange prescribing patterns for Guillain-Barre Syndrome in the United States-2001 to 2018. Muscle Nerve 2024; 70:1192-1199. [PMID: 39324188 PMCID: PMC11560546 DOI: 10.1002/mus.28265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2024] [Revised: 09/09/2024] [Accepted: 09/16/2024] [Indexed: 09/27/2024]
Abstract
INTRODUCTION/AIMS Randomized controlled trials show that repeat intravenous immunoglobulin (IVIG) dosing and plasma exchange (PLEX) followed by IVIG (combination therapy) have no additional therapeutic benefit in Guillain-Barre Syndrome (GBS) non-responders. Furthermore, the delineation between GBS and Acute Onset CIDP (A-CIDP) can be particularly challenging and carries therapeutic implications. We aimed to evaluate the presence of repeat IVIG, combination therapy, and diagnostic reclassification from GBS to CIDP. METHODS We performed a retrospective study of a large healthcare database for patients with GBS in the US from 2001 to 2018. We identified individuals initially diagnosed with GBS and later re-classified as CIDP. Multivariable logistic regression models were developed to determine associations between patient factors and repeat IVIG dosing, combination therapy, and diagnostic re-classification from GBS to CIDP. RESULTS We identified 2325 patients with GBS. A total of 39.7% received repeat IVIG and 6.1% received combination therapy. The proportion of individuals initially diagnosed with GBS and then re-classified as CIDP was 32.0%. Repeat IVIG, combination therapy, and diagnostic reclassification remained stable over time. Female sex (OR 0.79, 95% CI 0.65-0.96) and medium-high net worth (OR 0.64, 95% CI 0.45-0.90) associated with repeat IVIG therapy, while Asian ethnicity associated with diagnostic re-classification from GBS to CIDP (OR 1.77, 95% CI 1.09-2.86). DISCUSSION Repeat IVIG dosing was quite common in GBS before newer trials suggesting harm in non-responders, and IVIG/PLEX combination therapy continues to persist despite strong evidence against use in non-responders. Further, nearly one in three patients initially diagnosed with GBS is subsequently diagnosed with CIDP, but the reasons are unclear.
Collapse
Affiliation(s)
- Amro M. Stino
- Department of Neurology, University of Michigan, Ann Arbor, MI, USA
| | - Evan L. Reynolds
- Department of Neurology, University of Michigan, Ann Arbor, MI, USA
| | - Maya Watanabe
- Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
| | | |
Collapse
|
2
|
Khan SA, Das PR, Nahar Z, Dewan SMR. An updated review on Guillain-Barré syndrome: Challenges in infection prevention and control in low- and middle-income countries. SAGE Open Med 2024; 12:20503121241239538. [PMID: 38533198 PMCID: PMC10964449 DOI: 10.1177/20503121241239538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2023] [Accepted: 02/28/2024] [Indexed: 03/28/2024] Open
Abstract
Guillain-Barré syndrome is a rare condition that can be potentially life-threatening. Guillain-Barré syndrome does not have a definitive etiological agent. It is a syndrome that can arise from multiple factors, including various infectious diseases and immunizations. The severity of Guillain-Barré syndrome is exacerbated by these variables, especially in low-income and middle-income countries where healthcare systems are already constrained and struggle to meet the demands of other diseases. The primary aim of our article is to comprehensively examine the life-threatening nature and intensity of Guillain-Barré syndrome by assessing its etiology, progression, and prevalence in low- and middle-income nations while also considering global trends. Furthermore, we proposed the implementation of standard and efficacious treatment and diagnostic resources that are readily accessible and successful in affluent nations and should also be readily accessible in impoverished nations without any unnecessary delay. Our study also emphasized the epidemiological data with molecular epidemiological analysis and the utilization of artificial technology in low- and middle-income nations. The goal was to decrease the incidence of Guillain-Barré syndrome cases and facilitate early detection.
Collapse
Affiliation(s)
- Sakif Ahamed Khan
- Department of Pharmacy, School of Medicine, University of Asia Pacific, Dhaka, Bangladesh
| | - Proma Rani Das
- Department of Pharmacy, School of Medicine, University of Asia Pacific, Dhaka, Bangladesh
| | - Zabun Nahar
- Department of Pharmacy, School of Medicine, University of Asia Pacific, Dhaka, Bangladesh
| | | |
Collapse
|
4
|
Tiwari I, Alam A, Kanta C, Koonwar S, Garg RK, Pandey S, Jain A, Kumar R. Clinical Profile and Predictors of Mechanical Ventilation in Guillain-Barre Syndrome in North Indian Children. J Child Neurol 2021; 36:453-460. [PMID: 33331796 DOI: 10.1177/0883073820978020] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
OBJECTIVE To describe the clinical-laboratory profile of pediatric Guillain-Barre syndrome and delineate features associated with need of mechanical ventilation. METHODS In a prospective observational study at tertiary care hospital, clinical-laboratory assessment and nerve conduction studies were documented in consecutive children hospitalized with Guillain-Barre syndrome according to Brighton criteria. Clinical-laboratory features were compared between ventilated and nonventilated patients using univariate and multivariate analysis. RESULTS Forty-six children (27 boys) with a mean age of 69.1±35.2 months were enrolled. History of preceding infection was present in 47.8%, bulbar palsy in 43.5%, feeble voice in 41.3%, sensory involvement in 13%, and autonomic involvement in 39.5%. Tetraparesis was noted in 87% of cases. Hughes disability scale >3 was noted in 44 children at admission and 39 (84.7%) at discharge. The most common electrophysiological type was acute motor axonal neuropathy (46.5%) followed by acute motor sensory axonal neuropathy (39.5%), acute inflammatory demyelinating polyneuropathy (7%), and inexcitable nerves (7%). Nine (19.7%) children were ventilated, 3 (6.5%) died or were lost, and 43 were discharged. Factors associated with need of mechanical ventilation on univariate analysis were older age, hypertension, bulbar palsy, feeble voice, lower Medical Research Council (MRC) sum, raised total leucocyte count, and history of preceding infection. Logistic regression revealed older age, history of predisposing illness, lower MRC sum at presentation, and bulbar palsy as independent predictors of mechanical ventilation. CONCLUSIONS The most common electrophysiological subtype in northern Indian children is acute motor axonal neuropathy. Older age, preceding infection, low MRC sum, and bulbar palsy are predictors of mechanical ventilation in pediatric Guillain-Barre syndrome.
Collapse
Affiliation(s)
- Ishita Tiwari
- Departments of Pediatrics, 76140King George's Medical University, Lucknow, Uttar Pradesh, India
| | - Areesha Alam
- Departments of Pediatrics, Era's Lucknow Medical College & Hospital, Lucknow, Uttar Pradesh, India
| | - Chandra Kanta
- Departments of Pediatrics, 76140King George's Medical University, Lucknow, Uttar Pradesh, India
| | - Sciddhartha Koonwar
- Departments of Pediatrics, 76140King George's Medical University, Lucknow, Uttar Pradesh, India
| | - Ravindra Kumar Garg
- Department of Neurology, 76140King George's Medical University, Lucknow, Uttar Pradesh, India
| | - Shweta Pandey
- Department of Neurology, 76140King George's Medical University, Lucknow, Uttar Pradesh, India
| | - Amita Jain
- Department of Microbiology, 76140King George's Medical University, Lucknow, Uttar Pradesh, India
| | - Rashmi Kumar
- Departments of Pediatrics, 76140King George's Medical University, Lucknow, Uttar Pradesh, India
| |
Collapse
|
5
|
Shang P, Zhu M, Baker M, Feng J, Zhou C, Zhang HL. Mechanical ventilation in Guillain-Barré syndrome. Expert Rev Clin Immunol 2020; 16:1053-1064. [PMID: 33112177 DOI: 10.1080/1744666x.2021.1840355] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Introduction: Up to 30% of patients with Guillain-Barré syndrome (GBS) develop respiratory failure requiring intensive care unit (ICU) admission and mechanical ventilation. Progressive weakness of the respiratory muscles is the leading cause of acute respiratory distress and respiratory failure with hypoxia and/or hypercarbia. Bulbar weakness may compromise airway patency and predispose patients to aspiration pneumonia. Areas covered: Clinical questions related to the use of mechanical ventilation include but are not limited to: When to start? Invasive or noninvasive? When to wean from mechanical ventilation? When to perform tracheostomy? How to manage complications of GBS in the ICU including nosocomial infection, ventilator-associated pneumonia, and ICU-acquired weakness? In this narrative review, the authors summarize the up-to-date knowledge of the incidence, pathophysiology, evaluation, and general management of respiratory failure in GBS. Expert opinion: Respiratory failure in GBS merits more attention from caregivers. Emergency intubation may lead to life-threatening complications. Appropriate methods and time point of intubation and weaning, an early tracheostomy, and predictive prophylaxis of complications benefit patients' long-term prognosis.
Collapse
Affiliation(s)
- Pei Shang
- Department of Neurology, First Hospital of Jilin University , Changchun, China.,Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science , Rochester, MN, USA
| | - Mingqin Zhu
- Department of Neurology, First Hospital of Jilin University , Changchun, China.,Departments of Laboratory Medicine and Pathology, Neurology and Immunology, Mayo Clinic , Rochester, MN, USA
| | - Matthew Baker
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science , Rochester, MN, USA
| | - Jiachun Feng
- Department of Neurology, First Hospital of Jilin University , Changchun, China
| | - Chunkui Zhou
- Department of Neurology, First Hospital of Jilin University , Changchun, China
| | - Hong-Liang Zhang
- Department of Life Sciences, National Natural Science Foundation of China , Beijing, China
| |
Collapse
|
7
|
Bhaskar S, Bradley S, Israeli-Korn S, Menon B, Chattu VK, Thomas P, Chawla J, Kumar R, Prandi P, Ray D, Golla S, Surya N, Yang H, Martinez S, Ozgen MH, Codrington J, González EMJ, Toosi M, Hariya Mohan N, Menon KV, Chahidi A, Mederer Hengstl S. Chronic Neurology in COVID-19 Era: Clinical Considerations and Recommendations From the REPROGRAM Consortium. Front Neurol 2020; 11:664. [PMID: 32695066 PMCID: PMC7339863 DOI: 10.3389/fneur.2020.00664] [Citation(s) in RCA: 55] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Accepted: 06/03/2020] [Indexed: 01/10/2023] Open
Abstract
With the rapid pace and scale of the emerging coronavirus 2019 (COVID-19) pandemic, a growing body of evidence has shown a strong association of COVID-19 with pre- and post- neurological complications. This has necessitated the need to incorporate targeted neurological care for this subgroup of patients which warrants further reorganization of services, healthcare workforce, and ongoing management of chronic neurological cases. The social distancing and the shutdown imposed by several nations in the midst of COVID-19 have severely impacted the ongoing care, access and support of patients with chronic neurological conditions such as Multiple Sclerosis, Epilepsy, Neuromuscular Disorders, Migraine, Dementia, and Parkinson disease. There is a pressing need for governing bodies including national and international professional associations, health ministries and health institutions to harmonize policies, guidelines, and recommendations relating to the management of chronic neurological conditions. These harmonized guidelines should ensure patient continuity across the spectrum of hospital and community care including the well-being, safety, and mental health of the patients, their care partners and the health professionals involved. This article provides an in-depth analysis of the impact of COVID-19 on chronic neurological conditions and specific recommendations to minimize the potential harm to those at high risk.
Collapse
Affiliation(s)
- Sonu Bhaskar
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Department of Neurology and Neurophysiology, Liverpool Hospital, Sydney, NSW, Australia
- Neurovascular Imaging Laboratory & NSW Brain Clot Bank, Ingham Institute for Applied Medical Research and South West Sydney Clinical School, The University of New South Wales, UNSW Medicine, Sydney, NSW, Australia
| | - Sian Bradley
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- The University of New South Wales, UNSW Medicine, Sydney, NSW, Australia
| | - Simon Israeli-Korn
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Department of Neurology, Sheba Medical Center, Tel Hashomer, Ramat Gan and Sackler School of Medicine, Movement Disorders Institute, Tel Aviv University, Tel Aviv-Yafo, Israel
| | - Bindu Menon
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Department of Neurology, Apollo Hospitals, Nellore, India
| | - Vijay Kumar Chattu
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada
| | - Pravin Thomas
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Department of Neurology, University Hospitals NHS Foundation Trust, Birmingham, United Kingdom
| | - Jasvinder Chawla
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Department of Neurology, Loyola University Medical Center & Hines VA Hospital, Chicago, IL, United States
| | - Rajeev Kumar
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Department of Psychiatry, Hamad Medical Center, Qatar & Australian National University, Canberra, ACT, Australia
| | - Paolo Prandi
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Department of Neurology, University of Eastern Piedmont Amedeo Avogadro, Novara, Italy
| | - Daniel Ray
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Farr Institute of Health Informatics, University College London (UCL) & NHS Foundation Trust, Birmingham, United Kingdom
| | - Sailaja Golla
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Texas Institute for Neurological Disorders, Dallas, TX, United States
| | - Nirmal Surya
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Department of Neurology, Bombay Hospital & Medical Research Centre, and Epilepsy Foundation India, Mumbai, India
| | - Harvey Yang
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Department of Neurology, Academic Hospital Paramaribo & Anton de Kom Universiteit van Suriname Faculteit der Medische Wetenschappen, Paramaribo, Suriname
| | - Sandra Martinez
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Department of Neurology, Hospital da Restauração, Recife, Brazil
| | - Mihriban Heval Ozgen
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Department of Psychiatry, Parnassia Psychiatric Institute, The Hague, Netherlands
- Curium-Leiden University Medical Centre, Oegstgeest, Netherlands
| | - John Codrington
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Department of Laboratory Medicine, Academic Hospital Paramaribo and Anton de Kom Universiteit van Suriname Faculteit der Medische Wetenschappen, Paramaribo, Suriname
| | - Eva María Jiménez González
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Department of Forensic Psychology, Forensic Psychology and Forensic Sciences Institute, Ministry of Justice, Granada, Spain
| | - Mandana Toosi
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- LodeStone Center for Behavioral Health and Eastern Illinois University, Chicago, IL, United States
| | - Nithya Hariya Mohan
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Chengalpattu Medical College and Hospital, Chengalpattu, India
| | - Koravangattu Valsraj Menon
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Department of Psychiatry, South London and Maudsley NHS Foundation Trust, Kings Health Partners, London, United Kingdom
| | - Abderrahmane Chahidi
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- ED 268, DR 178, Sorbonne Nouvelle University, Paris, France
- Moroccan Society of Neurophysiology, Marrakech, Morocco
- Morocco and Basic and Clinical Neurosciences Research Laboratory, University Medical School of Marrakech, Marrakech, Morocco
| | - Susana Mederer Hengstl
- Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium, Chronic Neurology REPROGRAM Sub-committee†
- Department of Neurology, Complejo Hospitalario de Pontevedra, Pontevedra, Spain
| |
Collapse
|
8
|
Guillain-Barré syndrome in a heart transplantation recipient. J Am Assoc Nurse Pract 2020; 33:639-645. [PMID: 32282569 DOI: 10.1097/jxx.0000000000000400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2019] [Accepted: 01/16/2020] [Indexed: 11/26/2022]
Abstract
ABSTRACT A rare case of a heart transplantation recipient with Guillain-Barré syndrome occurred, which was associated with peripheral nervous system damage. Based on a review of epidemiological research, the symptom development process, and diagnostic tools, the authors highlight the extreme rarity of this postinfectious immune disease. After diagnosis, plasma exchange and immunoregulatory therapy should be performed because they result in rapid recovery. If there is delayed diagnosis and treatment, there is a high risk of disability or death. When patients experience acute limb paralysis as the main symptom, nurse practitioners (NPs) should focus on the patient's history, particularly with regard to infectious agents. Closely monitoring the patient to detect respiratory failure and the need for early respiratory intervention can help the patient to avoid the severe complication of permanent brain injury. For NPs, performance of early differential diagnosis is important, especially among patients who have immunosuppressive dependence after transplantation.
Collapse
|